Cargando…

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

AIMS/HYPOTHESIS: Additional safe and effective therapies for type 2 diabetes are needed, especially ones that do not cause weight gain and have a low risk of hypoglycaemia. The present study evaluated albiglutide as monotherapy. METHODS: In this placebo-controlled study, 309 patients (aged ≥18 years...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nauck, Michael A., Stewart, Murray W., Perkins, Christopher, Jones-Leone, Angela, Yang, Fred, Perry, Caroline, Reinhardt, Rickey R., Rendell, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705137/ https://www.ncbi.nlm.nih.gov/pubmed/26577795 http://dx.doi.org/10.1007/s00125-015-3795-1

Ejemplares similares

Once-weekly albiglutide in the management of type 2 diabetes: patient considerations
por: Woodward, Heather N, et al.
Publicado: (2014)

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing
por: Rosenstock, Julio, et al.
Publicado: (2009)

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
por: Buse, John B., et al.
Publicado: (2010)

An overview of the once‐weekly GLP‐1 receptor agonists from the pharmacist’s perspective
por: Patel, Dhiren
Publicado: (2020)

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial
por: Rosenstock, Julio, et al.
Publicado: (2020)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
por: Onishi, Yukiko, et al.
Publicado: (2012)

Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study
por: Darpo, Borje, et al.
Publicado: (2014)

Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
por: Trujillo, Jennifer
Publicado: (2020)

Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes
por: Di Dalmazi, Giulia, et al.
Publicado: (2022)

Erratum to: Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study
por: Darpo, Borje, et al.
Publicado: (2014)

Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
por: Heile, Michael, et al.
Publicado: (2018)

Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
por: Seno, Takahiro, et al.
Publicado: (2016)

Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
por: Goldman, Jennifer D.
Publicado: (2020)

Energy Balance in Hypothalamic Obesity in Response to Treatment with a Once-Weekly GLP-1 Receptor Agonist
por: Shoemaker, Ashley H., et al.
Publicado: (2022)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao, Qing, et al.
Publicado: (2016)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
por: Macdougall, Iain C
Publicado: (2007)

Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use
por: Kalra, Sanjay, et al.
Publicado: (2015)

Glycaemic and non‐glycaemic efficacy of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
por: Patel, Dhiren
Publicado: (2020)

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
por: Nauck, Michael A., et al.
Publicado: (2011)

Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study1,2
por: Ratner, R, et al.
Publicado: (2010)

Comparison of Usability, Accuracy, Preference, and Satisfaction Among Three Once-Weekly GLP-1 Receptor Agonist Pen Devices
por: Zhou, Anna Y., et al.
Publicado: (2018)

Managing the multifaceted nature of type 2 diabetes using once‐weekly injectable GLP‐1 receptor agonist therapy
por: Bzowyckyj, Andrew
Publicado: (2020)

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes
por: Kaneko, Shizuka
Publicado: (2022)

Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study
por: Nauck, Michael A., et al.
Publicado: (2009)

A review of GLP‐1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once‐weekly agents
por: Cornell, Susan
Publicado: (2020)

Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China
por: Ruan, Zhen, et al.
Publicado: (2022)

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A ≥52-week randomized, double-blind study
por: Yki-Järvinen, Hannele, et al.
Publicado: (2013)

Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study
por: Volpe, Sara, et al.
Publicado: (2022)

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
por: Bajaj, Harpreet S., et al.
Publicado: (2021)

Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks
por: Bergenstal, R M, et al.
Publicado: (2013)

Weekly glucagon‐like peptide‐1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled study
por: Nino, Antonio, et al.
Publicado: (2017)

Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once‐weekly dulaglutide AWARD programme
por: Dungan, K. M., et al.
Publicado: (2016)

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial
por: Johannsson, Gudmundur, et al.
Publicado: (2018)

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
por: Johansen, Pierre, et al.
Publicado: (2019)

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)
por: Riddle, Matthew C., et al.
Publicado: (2013)

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
por: Nauck, Michael, et al.
Publicado: (2014)

The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
por: Vidal, Josep, et al.
Publicado: (2020)

Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study
por: Odawara, M., et al.
Publicado: (2016)

Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
por: Kaku, Kohei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8vdmfr6465l76pq5nt0vct1dni